Effects of bone-targeted agents on cancer progression and mortality

Journal of the National Cancer Institute

Volumn 104, Issue 14, 2012, Pages 1059-1067

  Coleman, Robert ^a   Gnant, Michael ^a   Morgan, Gareth ^a   Clezardin, Philippe ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DENOSUMAB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GELATINASE B; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; PAMIDRONIC ACID; PLACEBO; TAMOXIFEN; THALIDOMIDE; TRASTUZUMAB; VASCULOTROPIN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; BLADDER CARCINOMA; BONE CANCER; BONE MARROW BIOPSY; BONE METASTASIS; BONE PAIN; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC MYELOID LEUKEMIA; CLIMACTERIUM; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; META ANALYSIS (TOPIC); METASTASIS; MORBIDITY; MULTIPLE MYELOMA; MYELOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVERALL SURVIVAL; PANCREAS CARCINOMA; PATHOLOGIC FRACTURE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GOSERELIN; HUMANS; IMIDAZOLES; MALE; MENOPAUSE; NEOPLASMS; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84864482354     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs263     Document Type: Review

References (83)

1. Costa L, Harper P, Coleman RE, Lipton A. Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol. 2011;77(suppl 1):S31-S37.
2. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial. Lancet. 2010;376(9757):1989-1999.
3. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Eng J Med. 2009;360(7):679-691.
4. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39-46.
5. Melton LJ III, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV (2005) Fracture risk with multiple myeloma: A population-based study. J Bone Miner Res. 2005;20(3):487-493.
6. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314-3321.
7. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol.1999;17(3):846-854.
8. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 2010;12(6):214-227.
9. Wilson C, Coleman RE. Seed, soil and secreted hormones: Potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates [published online ahead of print March 5, 2012]. Cancer Treat Rev. doi:10.1016/j.ctrv.2012. 02.007.
10. Zipori D. The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell. Cancer Microenviron. 2010;3(1):15-28.
11. Mitsiades CS, McMillin DW, Klippel S, et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007;21(6):1007-1034.
12. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A. 2003;100:7737-7742.
13. Zhang K, Kim S, Cremasco V, et al. CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Res. 2011;71(14):4799-4808.
14. Morgan GJ. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma? Crit Rev Oncol Hematol. 2011;77(suppl 1):S24-S30.
15. Jagannath S. Pathophysiological underpinnings of multiple myeloma progression. J Manag Care Pharm. 2008;14(suppl 7):7-11.
16. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464-2472.
17. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol.2008;19(3):420-432.
18. Ottewell PD, Deux B, Monkkonen H, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008;14(14):4658-4666.
19. Clézardin P. Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class. Bone 2011;48(1):71-79.
20. Li X, Liao J, Park SI, et al. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone. Bone. 2011;48(6):1354-1361.
21. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008;100(16):1167-1178.
22. Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009;15(8):960-966.
23. Woodward EJ, Coleman RE. Prevention and treatment of bone metastases. Curr Pharm Des. 2010;16(27):2998-3006.
24. Malinin NL, Pluskota E, Byzova TV. Integrin signaling in vascular function. Curr Opin Hematol. 2012;19(3):206-211.
25. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307.
26. Dudley AC, Udagawa T, Melero-Martin JM, et al. Bone marrow is a reservoir for pro-angiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors. Blood. 2010;116:3367-3371.
27. Coscia M, Quaglino E, Lezzi M, et al. Zoledronic acid repolarizes tumour associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010;14:2803-2815.
28. Clézardin P, Massaia M. Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr Pharm Des. 2010;16:3007-3014.
29. Benzaïd I, Mönkkönen H, Stresing V, et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011;71(13):4562-4572.
30. Maniar A, Zhang X, Lin W, et al. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood. 2010;116(10):1726-1733.
31. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol. 2007;24(2):227-230.
32. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001;113(4):1035-1043.
33. Morgan GJ, Child JA, Gregory WM, et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): Secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011;12(8):743-752.
34. Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia. 2010;24(5):1043-1049.
35. Ural AU, Yilmaz MI, Avcu F, et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol. 2003;78(5):443-449.
36. Schmidmaier R, Simsek M, Baumann P, Emmerich B, Meinhardt G. Synergistic antimyeloma effects of zoledronate and simvastatin. Anticancer Drugs. 2006;17(6):621-629.
37. Moschetta M, Di Pietro G, Ria R, et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer. 2010;46(2):420-429.
38. Guenther A, Gordon S, Tiemann M, et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer. 2010;126(1):239-246.
39. Brown JE, Coleman RE. Denosumab in patients with cancer-A surgical strike against the osteoclast. Nat Rev Clin Oncol. 2012;9(2):110-118.
40. Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res. 2011;17(6):1278-1286.
41. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564-1571.
42. Vij R, Horvath N, Spencer A, et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol. 2009;84(10):650-656.
43. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-1132.
44. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow-A long term follow up. Ann Oncol. 2007;19(12):2007-2011.
45. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in nodepositive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001;19(1):10-17.
46. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002;20(15):3219-3224.
47. Green JR. Bisphosphonates: Preclinical review. Oncologist. 2004;9(suppl 4):3-13.
48. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010;21(11):2188-2194.
49. Coleman RE, Marshall H, Cameron D, et al. on behalf of the AZURE Investigators. Breast cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365(15):1396-1405.
50. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase 2 trial. Lancet Oncol. 2010;11(5):421-428.
51. Rack B, Juckstock J, Genss EM, et al. Effect of zoledronic acid on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res. 2010;30(5):1807-1813.
52. Solomayer EF, Gebauer G, Hirnie P, et al. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients [published online ahead of print March 1, 2012]. Ann Oncol. PMID:22383680; doi:10.1093/annonc/ mdr612.
53. Gnant M, Mlineritsch B, Stoeger H, et al. on behalf of the Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631-641.
54. Gnant M, Mlinteritsch B, Luschin-Ebengreuth G, et al. Long-term followup in ABCSG-12: Significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. Cancer Res. 2011;71(suppl 24):absS1-2,95s.
55. Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012;118(5):1192-1201.
56. Llombart A, Frassoldati A, Paija O, et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Ann Oncol. 2010;21(11):2188-2194.
57. de Boer R, Bundred N, Eidtmann H, et al. Long-term survival outcomes among postmenopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5-year follow- up of ZO-FAST. Cancer Res. 2011;71(suppl 24):absS1-3,96s.
58. Paterson AHG, Anderson SJ, Lembersky BC, et al. NSABP protocol B-34: A clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy-final analysis. Cancer Res. 2011;71(suppl 24):absS2-3,100s.
59. Mobus V, Diel I, Harbeck N, et al. GAIN (German Adjuvant Intergroup Node Positive) Study: A phase-III multicenter trial to compare dose dense, dose intense ETC (iddETC) vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer-1st interim efficacy analysis. Cancer Res. 2011;71(suppl 24):absS2-4,100s.
60. Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. ClinicalTrials.gov. NCT00127205.
61. Study to determine treatment effects of denosumab in patients with breast cancer receiving aromatase inhibitor therapy. ClinicalTrials.gov. NCT00556374.
62. Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE). ClinicalTrials.gov. NCT01077154.
63. Nicks KM, Fowler TW, Akel NS, et al. Bone turnover across the menopausal transition, the role of gonadal inhibins. Ann N Y Acad Sci. 2010;1192:153-160.
64. Saad F. New research findings on zoledronic acid: Survival, pain, and antitumour effects. Cancer Treat Rev. 2008;34(2):183-192.
65. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23(22):4925-4935.
66. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97(1):59-69.
67. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113(1):193-201.
68. Coleman R, Cook R, Saad F, et al. Meta-analysis of effects of zoledronic acid (ZOL) on survival in patients with metastatic bone disease (MBD) and high bone turnover. Cancer Treat Rev. 2008;34(suppl 1):S86.
69. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 2008;3(3):228-236.
70. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860-1867.
71. Saad F, Sternberg CN. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. Nat Clin Pract Urol. 2007;4(suppl 1):S3-13.
72. Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009;10(9): 872-876.
73. Mystakidou K, Katsouda E, Parpa E, Kelekis A, Galanos A, Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol. 2005;22(2):195-201.
74. Zaghloul MS, Boutrus R, El-Hosieny H, A-Kader Y, El-Attar I, Nazmy M. A prospective randomized placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer patients [abstract]. Int J Clin Oncol. 2010;15(4):382-389.
75. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer. 2009;125(7):1705-1709.
76. A study to evaluate the safety and efficacy of zoledronic acid in the prevention or delaying of bone metastasis in patients with stage IIIA and IIIB non-small cell lung cancer (NSCLC). ClinicalTrials.gov. NCT00172042.
77. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet. 1998;352(9132):930-942.
78. Poole C, Earl H, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate and fluoruracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-1862.
79. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node positive breast cancer. N Engl J Med. 2005;352(22):2302-2313.
80. Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-784.
81. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-1141.
82. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2006;353:2747-2757.
83. Gianni L, Dafni U, Gelber R, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2 positive early breast cancer: A 4-year follow up of a randomized controlled trial. Lancet Oncol. 2011;12(3):236-244.